Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven diseases, today announced the appointment of Karen J. Ferrante, M.D. as head of R&D and chief medical officer. Dr. Ferrante, formerly oncology therapeutic area head for Takeda Pharmaceuticals and the Takeda Cambridge, USA site head, brings nearly 20 years of drug development experience and proven leadership in the pharmaceutical industry to Tokai.
Help employers find you! Check out all the jobs and post your resume.
